Abstract:The phospholipase C enzyme PLCγ2 is best characterised in the context of immune cell regulation. Furthermore, many mutations discovered in PLCγ2 have been linked to the development of complex immune disorders as well as resistance to ibrutinib treatment in chronic lymphocytic leukaemia. Importantly, it has also been found that a rare variant of PLCγ2 (P522R) has a protective role in Alzheimer's disease (AD). Despite initial characterisation of these disease-linked variants, a comprehensive understanding of their differences and underpinning molecular mechanisms, needed to facilitate therapeutic efforts, is lacking. Here, we used available structural insights for PLCγ enzymes to further analyse PLCγ2 M1141K mutation, representative for mutations in immune disorders and cancer resistance, and the AD-protective variant, PLCγ2 P522R. Together with several other mutations in the autoinhibitory interface, the PLCγ2 M1141K mutation was strongly activating in a cell-based assay, under basal and stimulated conditions. Measurements of PLC activity in various in vitro assays demonstrated enhanced activity of PLCγ2 M1141K while the activity of PLCγ2 P522R was not significantly different from the WT. Similar trends were observed in several other assays, including direct liposome binding. However, an enhanced rate of phosphorylation of a functionally important tyrosine by Btk in vitro was observed for PLCγ2 P522R variants. To further assess implications of these in vitro findings in a cellular context relevant for the PLCγ2 P522R variant, microglia (BV2) stable cell lines were generated and analysed under growth conditions. The PLC activity in cells expressing PLCγ2 P522R at physiologically relevant levels was clearly enhanced compared to the WT, and differences in cell morphology observed. These data, combined with the structural insights, suggest that the PLCγ2 P522R variant has subtle, localised structural changes that do not directly affect the PLC activity by compromising autoinhibition, as determined for PLCγ2 M1141K. It is also likely that in contrast to the PLCγ2 M1141K, the functional impact of the P522R substitution completely depends on further interactions with upstream kinases and other regulatory proteins in a relevant cellular context, where changes in the PLCγ2 P522R variant could facilitate processes such as phosphorylation and protein-protein interactions.

Crystal structure of Alzheimer's disease phospholipase D3 provides a molecular basis for understanding its normal and pathological functions

Structure of human phospholipase D3, a single‐strand exonuclease associated with Alzheimer's disease

Structural and mechanistic insights into disease-associated endolysosomal exonucleases PLD3 and PLD4

Phospholipase D3 regulates TFEB/TFE3 metabolism to maintain lysosomal homeostasis

PLD3 in Alzheimer’s Disease

Phospholipase D, a Novel Therapeutic Target Contributes to the Pathogenesis of Neurodegenerative and Neuroimmune Diseases

Structural insights into phospholipase D function

PLD3 and PLD4 synthesize -BMP, a key phospholipid enabling lipid degradation in lysosomes

Crystal Structure of a Phospholipase D from the Plant-Associated Bacteria Serratia Plymuthica Strain AS9 Reveals a Unique Arrangement of Catalytic Pocket

PLD3 in Alzheimer’s Disease: a Modest Effect as Revealed by Updated Association and Expression Analyses

Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph

On the quaternary structure of human D‐3‐phosphoglycerate dehydrogenase

PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes

Localization of Phospholipase D in Detergent-insoluble, Caveolin-rich Membrane Domains

Role of conserved active site residues in catalysis by phospholipase B1 from Cryptococcus neoformans

Structural biology of cell surface receptors implicated in Alzheimer’s disease

The structure of iPLA2β reveals dimeric active sites and suggests mechanisms of regulation and localization

Common Variants In Pld3 And Correlation To Amyloid-Related Phenotypes In Alzheimer'S Disease

Characterisation of molecular mechanisms for PLCγ2 disease-linked variants

Impact of Common Variations in PLD3 on Neuroimaging Phenotypes in Non-demented Elders

An atomic structure of human γ-secretase